The Hepatocyte Growth Factor (HGF) and its receptor Met are physiological regulators of cell migration. HGF and Met have also been implicated in tumor progression and metastasis. We show here that the tyrosine kinase inhibitor STI571 has a stimulatory eect on HGFinduced migration and branching morphogenesis in thyroid cancer but not in primary or immortalized thyroid epithelial cells. These stimulatory eects of STI571 are observed at a concentration that is clinically relevant. The STI571-enhanced motile response can be correlated with an increase in the Met receptor tyrosine phosphorylation as well as ERK and Akt activation by HGF. Interestingly, one of the targets of STI571, namely the c-Abl tyrosine kinase, is activated by HGF and is recruited at the migrating edge of thyroid cancer cells. These data suggests that c-Abl and/or STI571-inhibited tyrosine kinases can negatively regulate the Met receptor to restrain the motile response in thyroid cancer cells. Oncogene (2001) 20, 3845 ± 3856.
Introduction
Cell migration is an important process in embryonic development, tissue remodeling, in¯ammatory response and wound repair. Cell migration can be regulated by a variety of extracellular factors, including extracellular matrix proteins (ECM), growth factors and chemokines. The ectopic migration of tumor cells during metastasis is a pathological condition that illustrates the importance of controlling the motile capability of cells. A number of physiological activators of the motile response have been identi®ed. These include peptide hormones, their respective receptor tyrosine kinases, intracellular adapter proteins, the small GTPases of the Rho family, phosphatidylinositol 3-kinase (PI3-K), the Extracellular Signal-Regulated Kinase (ERK), Focal Adhesion Kinase (FAK) and the Src tyrosine kinase (Kjoller and Hall, 1999; Parsons and Parsons, 1997; Sieg et al., 2000) .
An important regulator of cell migration during development is the Hepatocyte Growth Factor (HGF), that binds to and activates the Met receptor tyrosine kinase to stimulate cell motility, morphogenesis and proliferation (Stuart et al., 2000) . The hgf or c-met knockout mice die in utero and exhibit developmental defects in cell migration (Birchmeier and Gherardi, 1998) . Increased expression and/or activity of the Met receptor has been associated with tumor development and possibly tumor metastasis (Jiang et al., 1999; Stuart et al., 2000) . Indeed, overexpression of the Met receptor has been observed in a variety of human tumors, such as lung carcinoma, ovarian cancer, prostate (Stuart et al., 2000) and thyroid carcinoma (Di Renzo et al., 1995) . Furthermore, Met transfected ®broblasts exhibit anchorage-independent growth but are not tumorigenic in nude mice, consistent with a motogenic and invasive phenotype (Giordano et al., 1993) . In vitro, HGF promotes the dismantling of cellcell adhesion complexes and an epithelial-mesenchymal transition (Stuart et al., 2000) . In collagen matrix, after HGF stimulation, some cancer cells may form distal branching (Jiang et al., 1999) .
We have isolated a panel of human thyroid cancer cells that express a high level of the Met receptor and are responsive to the motogenic and morphogenic eect of HGF (Costantino et al., manuscript in preparation) . We have also derived normal thyroid epithelial cells in primary culture and SV40-LargeT Antigen-immortalized cells expressing a low level of Met receptor. In these cells, we examined the eect of STI571 on HGF-induced motogenic response. STI571 is a 2-phenylaminopyrimidine derivative that can inhibit several tyrosine kinases, including c-Abl, BcrAbl, PDGF receptor and the c-Kit receptor tyrosine kinases Heinrich et al., 2000; Wang et al., 2000) . In preclinical studies, STI571 has exhibited a speci®c ecacy in the treatment of chronic myelogenous leukemia (CML) without signi®-cant side eects and no apparent toxicity le Coutre et al., 1999) . In this study, we have uncovered a previously unknown eect of STI571 in stimulating the cellular response to HGF. We have found that STI571 can increase HGF-induced motility and HGF-induced branching morphogenesis in thyroid cancer cells through an enhancement of the Met receptor signaling.
Results

STI571 increases thyroid cancer cell motility
Previous studies have suggested that HGF (through the Met receptor) activates the PI3-Kinase, ERK and the Src kinase (Stuart et al., 2000) , which are involved in motility. We therefore examined the eect of inhibitors of PI3-Kinase (LY294002), MEK (PD98059) and Src (PP2) on HGF-induced motility.
For comparison, we also tested STI571, which is an inhibitor of several tyrosine kinases including c-Abl, PDGF-R and c-Kit. Figure 1a shows results of a migration assay performed with Ca 18/3, a papillary thyroid carcinoma cell line. In these migration assays, cells were moving across a membrane ®lter coated on the lower side with collagen and¯oated above medium with or without HGF (Methods). In the absence of HGF (Figure 1a , left, white bars), LY294002 (number 2) and PP2 (number 4) reduced cell migration by approximately 40% (compare 1 to 2) and 60% (compare 1 to 4) respectively, whereas PD98059 (number 3) was without eect. Surprisingly, STI571 (number 5) increased cell migration by approximately 60% (compare 1 to 5). In the presence of HGF ( Figure  1 , right, gray bars), migration increased by approximately 50% (number 6). Again, LY294002 (number 7) and PP2 (number 9) inhibited migration, whereas no eect of PD98059 (number 8) was observed on HGFstimulated migration (compare 6 to 8). Most remarkably, STI571 enhanced HGF-induced migration by approximately 200% (compare 6 to 10). We performed a dose response experiment with STI571 ( Figure 1b) . Cell migration was increased in a STI571 dosedependent manner with the maximal stimulation at 1.0 mM. These data suggest that, in thyroid cancer cells, STI571 has an enhancing eect on the basal as well as HGF-induced cell motility (Figure 1a) . Moreover, the eect of STI571 occurred within the clinically relevant concentrations (Figure 1b) .
Differential effect of STI571 in cancer versus primary thyroid cells
We examined the eect of STI571 on cell migration in 13 independently derived thyroid cancer cell lines (eight papillary, two follicular and three anaplastic). We also performed migration experiments with two thyroid cell lines, one established by immortalization with the SV40 T-antigen (DR-15) and the other at early passages, in primary culture (N12, see Materials and methods) (Figure 2 ). In the absence of HGF, STI571 increased migration in nine out of 13 thyroid cancer cell lines (Table 1 and Figure 2) ranging from 30% (CA 301,  Table 1 , left and Figure 2 ) up to 140% (BC-PAP, Table 1 , left and Figure 2 ). In the presence of HGF, STI571 signi®cantly enhanced HGF-induced migration in 10 out of 13 cancer cell lines (Table 1 and Figure 2) . In ARO and KAK cells, STI571 did not enhance basal Bergstrom et al., 1999) . Therefore, the stimulatory eect of STI571 on thyroid cancer cell migration may be dependent on the increased activity of the Met receptor. complexity of the branched structures ( Figure 3a , panels G/H). The stimulatory eect of STI571 on matrigel invasion was more evident in WRO than in Ca 18/3 cells ( Figure 3a) . The stimulatory eect of STI571 on HGF-induced morphogenesis was also observed with the Ca 301 cells (not shown). In matrigel cultures we also evaluated the eect of HGF and STI571 on cell proliferation. For this purpose, we seeded cells onto matrigel in 96-well plates and the number of viable cells was evaluated by XTT ( Figure  3b ) as described in Materials and methods. In both cell lines tested, HGF signi®cantly increased cell number ( Figure 3b , compare white to gray bars) indicating that HGF-induced branching morphogenesis is determined by both a change in cell shape and an increase in cell number. Importantly, STI571 did not signi®cantly aect cell proliferation (Figure 3b ), suggesting that STI571 in¯uenced the morphogenic rather than the mitogenic eect of HGF.
STI571 enhances Met receptor tyrosine phosphorylation
Previous studies have established STI571 as an inhibitor of the PDGF receptor, the c-Kit receptor and the c-Abl tyrosine kinases at submicromolar concentrations . In order to explain the eect of STI571 on thyroid cancer cells, we examined the expression of PDGF and c-Kit receptors on the WRO cell line, one of the most responsive to STI571 (Table 1, Figure 2 ). By Western blot, we detected the presence of PDGF-Rb (190 KDa, Figure 4b , lower panel) whereas we were not able to ®nd any expression of c-Kit (data not shown). Our Western blot data were in accordance with previous ®ndings showing the presence of PDGF-R in thyroid cancer cell lines and the loss of the expression of c-Kit in malignant thyroid cells (Natali et al., 1995; Tanaka et al., 1995) . In WRO cells we therefore examined the eect of dierent doses of STI571 on the general (Figure 4f , compare 1 to 3 and 2 to 4). These data support the idea that the enhancing eect of STI571 on motility and morphogenesis is due to an increase in the tyrosine phosphorylation/activation of the Met receptor. More importantly, the STI571 eect does not appear to be due to a modulation of the PDGF-R as it is not activated under the experimental conditions.
STI571 enhances the activation of ERK and Akt by HGF
Because STI571 increased the tyrosine phosphorylation of the Met receptor tyrosine kinase, we examined whether STI571 could aect the activation (phosphorylation) of ERK1/2 and Akt/PKB in HGF-stimulated cells (Figure 5a,b) . In the three thyroid cancer cell lines tested, the phosphorylation of ERK was consistently increased by HGF by 1.5 to twofold (Figure 5a , compare 1 to 2, 5 to 6 and 9 to 10). Treatment with STI571 alone caused a similar increase in ERK phosphorylation in Ca l8/3 and WRO cells ( Figure  5a , compare 1 to 3 and 9 to 11), but the combined eects of HGF and STI571 were not additive. With Ca 301 cells, STI571 did not increase the phosphorylation of ERK but enhanced the eect of HGF on ERK activation. We performed densitometric analysis of the phosphorylation of ERK2 from three independent experiments to establish the reproducibility of these results (Figure 5a, histogram) . We also investigated the stimulation of Akt phosphorylation by HGF in the three thyroid cancer cell lines tested (Figure 5b , compare 1 to 2, 5 to 6 and 9 to 10). Again, we observed a stimulatory eect on Akt phosphorylation by treatment with STI571 alone (Figure 5b , compare 1 to 3, 5 to 7 and 9 to 11). The combined treatment of HGF and STI571 further increased Akt phosphorylation in these thyroid cancer cells (Figure 5b, lanes 4, 8, 12) . Again, the enhanced activation of Akt by STI571 was reproducibly observed (Figure 5b , histogram). The enhancing eect of STI571 on the HGF-induced activation of ERK and Akt is consistent with its positive eect on HGF-induced cell motility.
c-Abl localizes to the migrating edge of HGF-stimulated cells
Because STI571 aects the activity of the c-Abl tyrosine kinase (Brasher and Van Etten, 2000; Schindler et al., 2000) , its eect could be in part due to the inhibition of c-Abl. The cytoplasmic c-Abl tyrosine kinase has been implicated in the regulation of cytoskeleton functions associated with cell adhesion, membrane ruing, neurite outgrowth and axon guidance (Lanier and Gertler, 2000; Lewis et al., 1996; Plattner et al., 1999) . We therefore examined the subcellular localization of c-Abl in the migrating cells. We scraped a monolayer of Ca 18/3 cells to generate a wounded edge and stained these cells with anti-Abl antibody and phalloidin (Figure 6a ). In response to the scraping, cells became polarized towards the wound (Nobes and Hall, 1999) (Figure  6a , arrow points to the wound). In the absence of HGF, we detected a diuse staining of c-Abl with a weak colocalization with F-actin at the leading edge ( Figure 6a , panels B/C). After stimulation with HGF, phalloidin-staining showed an increased number of pseudopodia ( Figure 6a , panel E), and the c-Abl signal became clearly detectable in these structures (Figure 6a 
HGF stimulates c-Abl tyrosine kinase in cells actively spreading onto extracellular matrix
To explore the role of c-Abl in HGF-induced responses, we evaluated the eect of HGF on c-Abl tyrosine kinase activity in Ca 18/3 and WRO cells by an in vitro kinase assay as described in Materials and methods. In serum-starved and subcon¯uent cells, 20 ng/ml HGF did not change c-Abl tyrosine kinase activity (data not shown). Since all the experiments in which we observed the enhancing eect of STI571 were carried out in the presence of extracellular matrix (matrigel, collagen IV), we performed HGF stimulation with Ca 18/3 and WRO allowed to spread onto collagen-coated plates as described in Materials and methods. In these conditions, HGF induced a signi®cant increase in Crk phosphorylation by the c-Abl tyrosine kinase (Figure 7a , upper panels). Densitometric analysis of dierent experiments, normalized for densitometric values of c-Abl protein (an example is shown in Figure 7a , lower panels), revealed a stimulation in c-Abl tyrosine kinase by HGF by approximately 50% in Ca 18/3 and 25% in WRO cells (Figure 7b ). These data suggest that in these cells c-Abl may be involved in the response to HGF to restrain the eect of activated Met.
Discussion
This study shows an enhancement of HGF-induced motility and morphogenesis by the tyrosine kinase inhibitor STI571 in a panel of thyroid cancer cells (Figures 1, 2 and 3 ). This enhancing eect of STI571 was not observed with inhibitors of PI-3, MEK and the Src tyrosine kinases (Figure 1 ). In thyroid cancer cells STI571 does not inhibit general protein tyrosine phosphorylation. On the contrary, we found that STI571 can enhance the Met receptor phosphorylation in the absence or the presence of HGF (Figure 4) . In STI571-treated cells we also observe an enhanced Akt and ERK activation by HGF ( Figure 5 ). Our data suggests that STI571 may act at an upstream point in the signaling cascade to enhance the Met receptor phosphorylation and thus increasing the signal output to multiple downstream targets, including ERK and Akt. However, we cannot rule out the possibility that STI571 may exert its eect on multiple pathways by inhibiting several dierent negative regulators. STI571 is an inhibitor of c-Abl, PDGF receptor and c-Kit tyrosine kinases . C-Kit receptor has been found in normal thyroid epithelial cells, but its expression dramatically decreases in malignant thyroid cells (Natali et al., 1995) . Consistent with the previous data, we did not detect the c-Kit protein in the WRO cells. Previous report have shown that thyroid cancer cells express PDGF-R (Heldin et al., 1988 (Heldin et al., , 1991 and in fact we detected PDGF-R by Western blot in the WRO cell line (Figure 4b) . Importantly, PDGF-R phosphorylation was not detected in serum-starved cells demonstrating that there is not a PDGF-R autocrine loop (Figure 4b) . Since all the experiments were performed under serum free conditions, it is unlikely that the STI571 eects could occur via the inhibition of the PDGF-R.
Because STI571 can also inhibit the c-Abl tyrosine kinase, its enhancing eect on HGF-induced response might be due to the inhibition of c-Abl activity. In this regard, the observation that c-Abl tyrosine kinase is activated by HGF and is recruited with the Met receptor at the migrating edge may be relevant ( Figures  6 and 7) . It is interesting to note that HGF did not stimulate the c-Abl tyrosine kinase in a monolayer of Ca 18/3 or WRO cells. However, HGF activated the cAbl tyrosine kinase in cells that were engaged to spread onto collagen (Figure 7) . Previous work has shown that the c-Abl tyrosine kinase is activated upon cell adhesion to the ECM (Lewis et al., 1996) . These previous observations together with the present results suggest that HGF might not directly activate the c-Abl tyrosine kinase. Rather, HGF could enhance the adhesion-mediated activation of c-Abl kinase by augmenting the adhesive response to collagen (Trusolino et al., 2000) . Because cell adhesion to and detachment from the ECM are integral components of cell movement, these results suggest that the c-Abl kinase might function locally at the migrating edge to integrate the HGF and the ECM signals and modulate the motile response.
The eect of STI571 on thyroid cancer cells suggests the existence of mechanisms to restrain Met receptor phosphorylation/activation and cell motility. Remarkably, these STI571-sensitive mechanisms do not appear to be present in normal thyroid cells. This dierent behavior of cancer and normal thyroid cells could not be correlated with levels of Met receptor expression (Bel®ore et al., 1997; Di Renzo et al., 1995) . We observed the enhancing eect of STI571 in thyroid cancer cells TPC-1 and WRO, which expressed the Met receptor at a level comparable to that of normal immortalized cells DR-15 (Figure 2 and Table 1 ). Another possibility is that the HGF-independent constitutive activity of Met receptor found in thyroid cancer cells (Costantino et al., manuscript in preparation; Bergstrom et al., 1999, 2000 and  Figure 5 ) may trigger a negative feedback loop to inhibit Met receptor signaling. The existence of these negative pathways may help to explain the apparent paradox in which a better prognosis was associated with a subset of thyroid tumors that overexpress the Met receptor (Bel®ore et al., 1997) . The unraveling of the STI571-sensitive pathways on cell motility may be important for the understanding of thyroid tumor progression and the metastatic potential of thyroid cancer cells.
Because of its ability to inhibit Bcr-Abl, PDGF-R and c-Kit tyrosine kinases, STI571 is being tested in the treatment of chronic myelogenous leukemia , glioblastoma (Kilic et al., 2000) and small cell lung carcinoma (Krystal et al., 2000) . Our data showing the enhancing eect of STI571 on HGF-induced response suggests that the overall biological eect of STI571 may be dependent upon the expression pattern of tyrosine kinases. Thus, the therapeutic ecacy of STI571 may be highly dependent on which tyrosine kinase pathway is activated in a speci®c cancer type. Protein A/G Sepharose was purchased from Pharmacia (Uppsala, Sweden). All the other reagents described were purchased from Fisher Scienti®c (Houston, TX, USA).
Materials and methods
Reagents and compounds
Cells
The papillary thyroid cancer cell lines Ca 18/3, Ca 286, Ca 298, Ca 300, Ca 301 and the anaplastic thyroid cancer cell line FF-1 were established in our laboratory from primary cultures. Normal thyroid cells in primary culture were prepared by dissociation of fresh normal thyroid tissue, collected at surgery, with collagenase IV (1 mg/ml in PBS at 378C in continuous rotation). DR-15 cell line was derived from normal thyroid cells by immortalization with SV-40 Large-T antigen. The papillary thyroid cancer cell lines BC-PAP, TPC-1, NPA, the follicular thyroid cancer cell lines WRO, FRO and the anaplastic thyroid carcinoma cell lines ARO, KAK were kindly provided by Dr A Fusco (Catanzaro, Italy). The expression degree of the Met receptor protein in these cell lines was assessed by densitometric analysis in anti-Met Western blot performed on crude cell lysate. To normalize Met expression levels, the same ®lters were re-probed with an anti-a-actin antibody (Sigma, St. Louis, MO, USA). All lines were grown in RPMI (Irvine Scienti®c, Santa Ana, CA, USA) or (in the case of DR-15) DMEM plus 10% FBS (Omega Scienti®c, Tarzana, CA, USA).
Migration assay
Migration assay was performed as previously described (Sieg et al., 1998) with the following modi®cations. Subcon¯uent thyroid cancer cells were preincubated with STI571 (0.1, 0.5, STI571 stimulates thyroid cancer cell migration F Frasca et al 1.0, 5.0 and 10 mM for 12 h) or with LY294002 (20 mM), PD98059 (50 mM) and PP2 (5 mM) for 1 h. Following preincubation, cells were then detached with PBS+5 mM EDTA, resuspended at 10 6 /ml. 10 5 cells, in serum free medium, and placed on 6.5 mm diameter polycarbonate ®lters (8 mM pore size, Costar, from Fisher Scienti®c), coated at the lower side with 250 mg/ml collagen IV. Then ®lters were placed over bottom chambers containing 500 ml of serum-free medium (RPMI or DMEM, depending on cell type) with or without HGF (20 ng/ml), STI571 (0.1, 0.5, 1.0, 5.0 and 10 mM), LY294002 (20 mM), PD98059 (50 mM), PP2 (5 mM) and incubated for 6 h at 378 with 5% CO 2 . At the end of 6 h, cells on the upper surface of the ®lters were removed with a cotton swab and the ®lters stained with crystal violet solution (0.05% crystal violet in PBS+20% ethanol). Filters were then placed in 24 multiwell plates containing 250 ml/well of 10% acetic acid and incubated for 30 min at room temperature under agitation to elute the dye. Samples were then measured at 590 nm. Row numbers obtained were reported as per cent of basal. Cell migration in these experiments is critically dependent on the coating of the ®lters with the appropriate matrix protein.
Preparation of cell lysate and Western blot
Subcon¯uent cells were incubated with 0.1, 0.5, 1.0, 10 mM STI571 in serum free medium for 12 h, stimulated with HGF for 10 min (1.0, 5.0 and 20 ng/ml) or PDGF-BB (20 ng/ml). Cells were washed twice with PBS (pH 7.4) and lysed in RIPA buer (150 mM NaCl, 1% Nonidet P-40, 50 mM Tris [pH 7.4], 10 mM sodium pyrophosphate, 100 mM NaF, 2 mM PMSF, 2 mM sodium vanadate, 10 mg/ml pepstatin, 10 mg/ml aprotinin, 10 mg/ml leupeptin). After being scraped, the samples were rotated for 15 min at 48C. Insoluble material was separated from soluble extract by microcentrifugation at 10 000 g for 10 min at 48C. The protein concentration was determined by the Bradford assay (BioRad, Hercules CA, USA). For immunoprecipitation 0.5 ± 1 mg proteins were incubated with 4 mg of the indicated antibodies and protein A/G sepharose. For Western blot on crude cell lysate, after addition of 56samples buer, samples (50 mg protein) were heated at 958C for 10 min. Immunoblottings were performed using 1 mg/ml of the indicated antibodies. All immunoblots were revealed by enhanced chemiluminescence (Amersham, Little Chalfont, UK), autoradiographed, and subjected to densitometric analysis. Densitometric results have been corrected for the total protein content.
Matrigel assay
Cells were collected and plated in a 48-multiwell (5610 3 cells/ well in 300 ml) previously coated with 300 ml of matrigel (BD Transduction Laboratories, San Diego, CA, USA). After 2 h, complete medium was replaced with serum free medium. Cells were allowed to grow and form tubule like-structures for 5 days in the presence or absence of STI571 (1 and 10 mM) and HGF (20 ng/ml). The medium and the stimulators were replaced every 2 days. The cells were scored with an inverted microscope at 106and 406magni®cation and photographed. To evaluate proliferation in matrigel, cells were plated in triplicate on a 96-multiwell (0.5 and 1.0610 3 cells/well in 100 ml) previously coated with 100 ml of matrigel. After 2 h, complete medium was replaced with serum free medium. Cells were allowed to grow for 5 days in the absence or presence of STI571 and HGF. Then, 50 ml of XTT solution (Roche Diagnostics Corporation, Indianapolis, IN, USA) was added and plates incubated for 4 h at 378C in the incubator. Absorbance was read at 470 nm, according to the manufacturer's instructions.
c-Abl in vitro kinase
Subcon¯uent cells were serum starved for 24 h. Cells were then detached by PBS+5 mM EDTA, resuspended in serum free medium, and kept in suspension for 1 h at 378C. After cells were allowed to attach onto collagen IV-coated (0.25 mg/ml) (Sigma, St. Louis, MI, USA) 100 mm Petri dishes in the presence/absence of HGF (20 ng/ml) for 30 min. After lysis and immunoprecipitation with anti-c-Abl polyclonal antibody (K12), samples were incubated for 40 min with 20 ml of a kinase mixture containing 1 mg GST-Crk, 10 mM ATP, 10 mCi 32 g-P-ATP (ICN, Costa Mesa, CA, USA) in Tris 10 mM [pH 7.4], 10 mM MgCl 2 , 1 mM DTT. The reaction was then stopped with Laemli buer, and samples were boiled for 10 min. After SDS ± PAGE, ®lters containing c-Abl and phosphorylated Crk were autoradiographed and then probed with anti-Abl antibody. C-Abl tyrosine kinase activity was quantitated by densitometric analysis of phosphorylated Crk, and normalized for the densitometric results obtained from anti c-Abl Western blot.
Indirect immunofluorescence
For studies in migrating cells under HGF stimulation, cells were grown on coverslips until con¯uent. These monolayers were wounded with a pipet tip and incubated in the presence/ absence of HGF (20 ng/ml) and STI571 (10 mM) in serum free medium for 6 h (Nobes and Hall, 1999) . Cells were ®xed with 3.7% formaldehyde for 20 min, washed once with PBS and then permeabilized for 10 min with 0.3% Triton X-100. Cells were blocked at room temperature for 1 h with 10% Normal Goat Serum and then incubated with monoclonal anti-Abl 8E9 antibody (30 mg/mL) or anti-Met (C-28) polyclonal antibody (5 mg/ml), or anti-Met monoclonal antibodies (DL-21, DO24) for 2 h. The cover slips were washed with PBS and incubated 1 h with goat anti-mouse or anti-rabbit secondary antibody Alexa Fluor 594, 488 (Molecular Probes, Eugene, OR, USA) or, in the case of cAbl/F-actin double staining, with Phalloidin-conjugated Alexa Fluor 488 (Molecular Probes). Cells were then washed again with PBS and stained with Hoechst 33258 (Sigma, St. Louis, MO, USA) to visualize the nuclei. After further washing, cover slips were mounted onto glass slides with gel mount (Biomeda, Foster City, CA, USA) and stored at 48C for 12 h in the dark. Epi¯uorescence microscopy was performed with a Nikon microscope and two-dimensional images were digitally acquired with a 0.606HRD060-NIK CCD-Camera (Diagnostic Instruments, Sterling Heights, MI, USA) using a 6061.40 oil objective. Images were merged using Image Pro Plus Software (Media Cybernetics, Silver Spring, MD, USA).
Statistical analysis
Migration experiments and Phosho-ERK/Akt results in response to HGF and STI571 were compared by two-way analysis of variance. Statistical analysis was carried out with Microsoft Excel software.
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